GlassScriptPhysician profile
Denise A Teves Qualler
NPI 1609827351
$55,850.50
in general payments reported to CMS, 2019-2025
10 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $10K · 2021: $4,812 · 2022: $5,550 · 2023: $1,466 · 2024: $235 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $990 · Food and Beverage: $951 · Travel and Lodging: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $990.00 |
| Food and Beverage | $950.67 |
| Travel and Lodging | $796.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $45,248.69 | 2019-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $8,759.03 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $641.00 | 2019-2025 | |
| Kyowa Kirin, INC. | $342.26 | 2023 | Crysvita |
| Novo Nordisk INC | $301.62 | 2019-2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $198.86 | 2019 | |
| Radius Health, INC. | $121.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.83 | 2019 | |
| Medtronic Minimed, INC. | $84.48 | 2019 | |
| Medtronic, INC. | $31.90 | 2023 | Minimed 770g, Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Teves Qualler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.